Search company, investor...
Search

Founded Year

2015

Stage

Series B | Alive

Total Raised

$139.4M

Last Raised

$100M | 8 mos ago

About Ori Biotech

Ori Biotech develops a proprietary, flexible manufacturing platform that closes, automates, and standardizes manufacturing, allowing therapeutics developers to further develop and bring their products from pre-clinical process development to commercial scale manufacturing. The company was founded in 2015 and is based in London, U.K.

Ori Biotech Headquarters Location

London Biosciences Innovation Centre 2 Royal College Street

London, England, NW1 0NH,

United Kingdom

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Ori Biotech's Products & Differentiation

See Ori Biotech's products and how their products differentiate from alternatives and competitors

  • TBD

    We are in the pre-launch phase

Expert Collections containing Ori Biotech

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Ori Biotech is included in 3 Expert Collections, including Biopharma Tech.

B

Biopharma Tech

5,241 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

A

Advanced Manufacturing

3,625 items

Companies focused on the technologies to increase manufacturing productivity, ranging from automation & robotics to AR/VR to factory analytics & AI, plus many more.

R

Robotics

2,342 items

This collection includes startups developing autonomous ground robots, unmanned aerial vehicles, robotic arms, and underwater drones, among other robotic systems. This collection also includes companies developing operating systems and vision modules for robots.

Ori Biotech Patents

Ori Biotech has filed 4 patents.

The 3 most popular patent topics include:

  • Biotechnology
  • Cell biology
  • Container terminals
patents chart

Application Date

Grant Date

Title

Related Topics

Status

5/20/2016

12/28/2021

Transcription factors, Clusters of differentiation, Cell biology, Biotechnology, Molecular biology

Grant

Application Date

5/20/2016

Grant Date

12/28/2021

Title

Related Topics

Transcription factors, Clusters of differentiation, Cell biology, Biotechnology, Molecular biology

Status

Grant

Latest Ori Biotech News

Manufacturing roundup: WuXi STA unveils new facility; Purdue University nets $3M grant for zero-waste pharma manufacturing

Sep 15, 2022

Tyler Patchen News Reporter CD­MO WuXi STA has been on the move re­cent­ly by break­ing ground on a fa­cil­i­ty in the US, and the com­pa­ny is show­ing no signs of stop­ping its ex­pan­sion dri­ve. The com­pa­ny an­nounced that it has opened a new ster­ile lipid nanopar­ti­cle man­u­fac­tur­ing site at its cam­pus in the city of WuXi, Chi­na. The fa­cil­i­ty has a mod­u­lar lay­out, al­low­ing for flex­i­bil­i­ty in the man­u­fac­tur­ing process, and can pro­duce 10 to 50 liters per batch. “We are pleased to sup­port our part­ners with this state-of-the-art LNP fa­cil­i­ty to meet the grow­ing de­mand for ad­vanced in­jec­tion dosage forms. We will con­tin­ue to ex­pand our CRD­MO plat­form’s ca­pac­i­ty and ca­pa­bil­i­ties to en­able our part­ners to ac­cel­er­ate more in­no­v­a­tive drugs to mar­ket for pa­tients world­wide,” said WuXi STA CEO Minzhang Chen in a state­ment . Pur­due Uni­ver­si­ty team nets grant to in­ves­ti­gate more sus­tain­able phar­ma­ceu­ti­cal man­u­fac­tur­ing Re­searchers at Pur­due Uni­ver­si­ty have se­cured a $3 mil­lion grant from the Na­tion­al Sci­ence Foun­da­tion to in­ves­ti­gate cost-ef­fec­tive, ze­ro-waste ini­tia­tives for phar­ma man­u­fac­tur­ing op­er­a­tions. Ac­cord­ing to the uni­ver­si­ty, cur­rent man­u­fac­tur­ing can cre­ate a sig­nif­i­cant amount of un­used med­i­cines and tox­ic waste, caus­ing en­vi­ron­men­tal dam­age and re­duc­ing man­u­fac­tur­ers’ prof­its. “Our project is fo­cused on cre­at­ing a large-scale frame­work and cy­ber­in­fra­struc­ture that can help man­u­fac­tur­ing net­works to per­form more sus­tain­ably. We’ll start our proof of con­cept with the phar­ma­ceu­ti­cal in­dus­try, giv­en its high im­pact on the Amer­i­can man­u­fac­tur­ing sys­tem dur­ing Covid,” said Shwe­ta Singh, project leader and as­so­ciate pro­fes­sor of Agri­cul­tur­al and Bi­o­log­i­cal En­gi­neer­ing and En­vi­ron­men­tal and Eco­log­i­cal En­gi­neer­ing, in a state­ment. The project will aim to build a “cir­cu­lar econ­o­my de­sign com­pu­ta­tion­al tool,” which will help com­pa­nies reuse re­sources while al­so re­duc­ing the flow of waste, and stands in stark con­trast to the more lin­ear forms of pro­duc­tion in the in­dus­try. The mod­el has al­ready been test­ed in agrar­i­an-based set­tings, and Singh’s team is work­ing with part­ners in the in­dus­try to de­vel­op and test the al­go­rithms. The team will al­so work to de­vel­op a pric­ing al­go­rithm as well for the re­cy­cling of waste med­i­cines for man­u­fac­tur­ing. Ori Biotech part­ners up with Re­silience and MD An­der­son joint ven­ture The joint ven­ture be­tween Re­silience and MD An­der­son to cre­ate a man­u­fac­tur­ing site for cell ther­a­pies has pulled in a new part­ner. Man­u­fac­tur­ing tech­nol­o­gy com­pa­ny Ori Biotech has part­nered up with the Cell Ther­a­py Man­u­fac­tur­ing Cen­ter (CTMC), the joint ven­ture that aims to cre­ate new cell ther­a­pies to fight can­cer. The col­lab­o­ra­tion will set its sights on in­dus­tri­al man­u­fac­tur­ing process­es for cell ther­a­pies. Ac­cord­ing to Ori, the part­ner­ship will in­clude com­bin­ing its tech­nol­o­gy plat­form with the man­u­fac­tur­ing cen­ter’s ca­pa­bil­i­ties. While the part­ner­ship has ze­roed in on work­ing on one cell ther­a­py now, it plans to work on oth­er Car-T process­es and de­ter­mine its “tech­ni­cal fea­si­bil­i­ty.” The part­ner­ship will al­so al­low the CTMC to gain pre-com­mer­cial ac­cess to Ori’s tech­nol­o­gy. “Ori and CTMC have specif­i­cal­ly part­nered with the goal of in­creas­ing pa­tient ac­cess to po­ten­tial­ly life-sav­ing cell ther­a­pies. This part­ner­ship will have a con­sid­er­able im­pact on the cell ther­a­py field by im­ple­ment­ing in­no­v­a­tive, dig­i­tal­ly en­abled process dis­cov­ery and au­to­mat­ed man­u­fac­tur­ing so­lu­tions,” said Ja­son Fos­ter, Ori Biotech’s CEO, in a state­ment. Man­u­fac­tur­er ac­quired by Sin­ga­pore-based pri­vate eq­ui­ty firm Ever­stone Cap­i­tal has ac­quired a con­trol­ling stake in the man­u­fac­tur­ing com­pa­ny Soft­gel Health­care. Soft­gel, an In­di­an-based dosage form man­u­fac­tur­ing op­er­a­tion, cre­ates over-the-counter phar­ma­ceu­ti­cal prod­ucts — main­ly pro­bi­otics and soft gelatin cap­sules. Ac­cord­ing to Sin­ga­pore-based Ever­stone Cap­i­tal, the ac­qui­si­tion will aim to build up Soft­gel and pro­vide the com­pa­ny with more re­sources. The fi­nan­cial terms of the deal were not dis­closed. Soft­gel, part of the Madras Phar­ma Group, al­so main­tains eight man­u­fac­tur­ing sites and R&D op­er­a­tions. “The com­pa­ny, with its strong R&D ca­pa­bil­i­ties and abil­i­ty to man­u­fac­ture prod­ucts in ad­vanced dosage forms, is well po­si­tioned to be a glob­al leader in the CD­MO seg­ment. We be­lieve that Ever­stone’s val­ue cre­ation play­book will help SH­PL re­al­ize its glob­al goals and pro­pel the com­pa­ny in­to its next phase of growth,” said Sameer Sain, Ever­stone Group CEO in a state­ment . AUTHOR Tyler Patchen News Reporter Over the past few days, the Biden administration has been focused on new science efforts, particularly around cancer , and growing biomanufacturing in the US. On Wednesday, the White House held a summit on biotech and biomanufacturing, revealing what it will spend to boost these efforts. Brian Deese, director of the National Economic Council, said that the administration has been focused on a modern industrial strategy by placing public funds in efforts that invest in infrastructure and secure supply chains. He also said that the focus of the initiative is to increase the domestic manufacturing of APIs to limit the dependence on foreign suppliers as well as increase the domestic manufacturing capacity in general and create jobs. Read More The NIH is all set to give a major push to the medicine AI community. As a part of its Bridge to Artificial Intelligence program (Bridge2AI), the NIH fund will invest $130 million over four years to promote the use of AI in biomedical and behavioral research. The goal is to generate new “flagship” data sets and create best practices for machine learning analysis. While AI is used in the biomedical and healthcare space, the NIH said that its adoption is not up to mark.“The biomedical research community generates a wealth of data, but most of these data are not suitable for machine learning because they are incomplete,” said the NIH on its website. Read More September 15, 2022 11:08 AM EDT

Ori Biotech Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Ori Biotech Rank

  • When was Ori Biotech founded?

    Ori Biotech was founded in 2015.

  • Where is Ori Biotech's headquarters?

    Ori Biotech's headquarters is located at London Biosciences Innovation Centre, London.

  • What is Ori Biotech's latest funding round?

    Ori Biotech's latest funding round is Series B.

  • How much did Ori Biotech raise?

    Ori Biotech raised a total of $139.4M.

  • Who are the investors of Ori Biotech?

    Investors of Ori Biotech include Amadeus Capital Partners, Delin Ventures, Octopus Ventures, Northpond Ventures, Chimera Investments and 5 more.

  • Who are Ori Biotech's competitors?

    Competitors of Ori Biotech include Cellares and 1 more.

  • What products does Ori Biotech offer?

    Ori Biotech's products include TBD.

You May Also Like

C
Cellares

Cellares is a cell therapy manufacturing technology startup in South San Francisco. Cellares is creating the future of cell therapy manufacturing and accelerating access to life-saving cell therapies. The company is developing a one-of-a-kind solution to overcome the limitations associated with manufacturing cell therapies to make them more affordable and widely available to patients in need. With Cellares' proprietary platform, The Cell Shuttle, biopharma companies, academic research centers and CDMOs will no longer have to compromise by either choosing a manufacturing platform that is semi-automated but lacks workflow flexibility, or one that provides customization but not the end-to-end automation needed to manufacture at scale.

Multiply Labs Logo
Multiply Labs

Pharmacube, dba Multiply Labs, was founded to provide individuals the freedom to customize their intake of supplements to optimize their day. Multiply Labs is leveraging robots and 3D printing to build made-to-order personal supplements, and people can also specify the duration of delivery for drugs like caffeine to take effect at the right time. In using patent-pending release technology developed at MIT and the University of Milan, Multiply Labs wants to change the way that people think about and take supplements.

Cellino Logo
Cellino

Cellino is developing an intracellular delivery technique for gene editing applications.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.